Category: CareFusion Corp.
Smiths Group takes its medical division off of the auction block after the division's H1 earnings drop hard and a multi-billion-dollar acquisition offer from CareFusion falls through.
ICU Medical manages to beat expectations despite a slide in sales for its 4th quarter, and the company names Vivek Jain its new CEO.
California-based ICU Medical (NSDQ:ICUI) posted a better-than-expected Q4, concurrently announcing the appointment of Vivek Jain as its new CEO.
Merger and acquisition activity in the medtech industry contracted 13% in 2013, with 41 deals worth a cumulative $14.3 billion coming in for the year, according to analysis from PricewaterhouseCoopers.
Total deal volume in the medical device industry contracted by about 13% in 2013, according to new analysis from audit shop PricewaterhouseCoopers.
The New England Journal of Medicine backs a 2010 study at the center of a controversy involving CareFusion's ChloraPrep antiseptic, the National Quality Forum and an alleged scheme to pay kickbacks to patient safety advocate Dr. Charles Denham.
A review by the New England Journal of Medicine of data from a 2010 study it published on CareFusion's (NYSE:CFN) ChloraPrep antiseptic found that both the company and the doctor in charge of the study acted appropriately, the journal told MassDevice.com today.
Terumo inks a pair of distribution deals, 1 to have its SurFlash catheters distributed in the U.S. by CareFusion and another to distribute Nonin's SenSmart universal oximetry system in the U.K. and Ireland.
Terumo Corp. (TYO:4543) sat on both sides of the table in inking a pair of distribution deals with CareFusion (NYSE:CFN) and Nonin Medical.
CareFusion's bottom line drops by 10% but hits the mark for analysts, who cast a cautiously optimistic eye on the year ahead.
Analysts are taking a cautious approach to CareFusion (NYSE:CFN) amid increasing costs and a 10% drip in profits for the company's 2nd quarter.
The New England Journal of Medicine tells MassDevice.com that its editors are reviewing a 2010 study published by the journal on the effectiveness of CareFusion's ChloraPrep in fighting surgical site infections after questions arise over financial links between the company and the study's lead author.